Trial Profile
Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2012
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 19 Jul 2011 New trial record